Inhibition of EP4 signaling attenuates aortic aneurysm formation

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Yokoyama, Utako ^a   Ishiwata, Ryo ^a,d   Jin, Mei Hua ^a   Kato, Yuko ^a   Suzuki, Orie ^a   Jin, Huiling ^a   Ichikawa, Yasuhiro ^a   Kumagaya, Syun ^a,d   Katayama, Yuzo ^a   Fujita, Takayuki ^a   Okumura, Satoshi ^a   Sato, Motohiko ^a   Sugimoto, Yukihiko ^b   Aoki, Hiroki ^c   Suzuki, Shinichi ^a   Masuda, Munetaka ^a   Minamisawa, Susumu ^d   Ishikawa, Yoshihiro ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c KURUME UNIVERSITY   (Japan)

^d WASEDA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; MONOCYTE CHEMOTACTIC PROTEIN 1; ONO AE1 329; ONO AE3 208; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ABDOMINAL AORTA ANEURYSM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG ACTIVITY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; TREATMENT DURATION; TREATMENT RESPONSE; UPREGULATION;

AGED; AGED, 80 AND OVER; ANGIOTENSIN II; ANIMALS; AORTA, ABDOMINAL; AORTIC ANEURYSM, ABDOMINAL; APOLIPOPROTEINS E; CELL LINE; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; FEMALE; GENE DELETION; HUMANS; INTERLEUKIN-6; MALE; MATRIX METALLOPROTEINASE 2; MICE; MICE, KNOCKOUT; MIDDLE AGED; MYOCYTES, SMOOTH MUSCLE; NAPHTHALENES; PHENYLBUTYRATES; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE; SIGNAL TRANSDUCTION; TISSUE CULTURE TECHNIQUES; UP-REGULATION;

MUS;

EID: 84860511327     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036724     Document Type: Article

References (33)

1. Annambhotla S, Bourgeois S, Wang X, Lin PH, Yao Q, et al. (2008) Recent advances in molecular mechanisms of abdominal aortic aneurysm formation. World J Surg 32: 976-986.
2. Collin J, Araujo L, Walton J, Lindsell D, (1988) Oxford screening programme for abdominal aortic aneurysm in men aged 65 to 74 years. Lancet 2: 613-615.
3. Scott RA, Ashton HA, Kay DN, (1991) Abdominal aortic aneurysm in 4237 screened patients: prevalence, development and management over 6 years. Br J Surg 78: 1122-1125.
4. Freestone T, Turner RJ, Coady A, Higman DJ, Greenhalgh RM, et al. (1995) Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 15: 1145-1151.
5. Walton LJ, Franklin IJ, Bayston T, Brown LC, Greenhalgh RM, et al. (1999) Inhibition of prostaglandin E2 synthesis in abdominal aortic aneurysms: implications for smooth muscle cell viability, inflammatory processes, and the expansion of abdominal aortic aneurysms. Circulation 100: 48-54.
6. Treska V, Kocova J, Boudova L, Neprasova P, Topolcan O, et al. (2002) Inflammation in the wall of abdominal aortic aneurysm and its role in the symptomatology of aneurysm. Cytokines Cell Mol Ther 7: 91-97.
7. Tieu BC, Lee C, Sun H, Lejeune W, Recinos A 3rd, et al. (2009) An adventitial IL-6/MCP1 amplification loop accelerates macrophage-mediated vascular inflammation leading to aortic dissection in mice. J Clin Invest 119: 3637-3651.
8. Guo DC, Papke CL, He R, Milewicz DM, (2006) Pathogenesis of thoracic and abdominal aortic aneurysms. Ann N Y Acad Sci 1085: 339-352.
9. Longo GM, Xiong W, Greiner TC, Zhao Y, Fiotti N, et al. (2002) Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest 110: 625-632.
10. Holmes DR, Wester W, Thompson RW, Reilly JM, (1997) Prostaglandin E2 synthesis and cyclooxygenase expression in abdominal aortic aneurysms. J Vasc Surg 25: 810-815.
11. Khan KM, Howe LR, Falcone DJ, (2004) Extracellular matrix-induced cyclooxygenase-2 regulates macrophage proteinase expression. J Biol Chem 279: 22039-22046.
12. Corcoran ML, Stetler-Stevenson WG, Brown PD, Wahl LM, (1992) Interleukin 4 inhibition of prostaglandin E2 synthesis blocks interstitial collagenase and 92-kDa type IV collagenase/gelatinase production by human monocytes. J Biol Chem 267: 515-519.
13. King VL, Trivedi DB, Gitlin JM, Loftin CD, (2006) Selective cyclooxygenase-2 inhibition with celecoxib decreases angiotensin II-induced abdominal aortic aneurysm formation in mice. Arterioscler Thromb Vasc Biol 26: 1137-1143.
14. Gitlin JM, Trivedi DB, Langenbach R, Loftin CD, (2007) Genetic deficiency of cyclooxygenase-2 attenuates abdominal aortic aneurysm formation in mice. Cardiovasc Res 73: 227-236.
15. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, et al. (2002) COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 360: 1071-1073.
16. McGettigan P, Henry D, (2006) Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 296: 1633-1644.
17. Yoshimura K, Aoki H, Ikeda Y, Fujii K, Akiyama N, et al. (2005) Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase. Nat Med 11: 1330-1338.
18. Segi E, Sugimoto Y, Yamasaki A, Aze Y, Oida H, et al. (1998) Patent ductus arteriosus and neonatal death in prostaglandin receptor EP4-deficient mice. Biochem Biophys Res Commun 246: 7-12.
19. Daugherty A, Manning MW, Cassis LA, (2000) Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 105: 1605-1612.
20. Yokoyama U, Minamisawa S, Adachi-Akahane S, Akaike T, Naguro I, et al. (2006) Multiple transcripts of Ca2+ channel alpha1-subunits and a novel spliced variant of the alpha1C-subunit in rat ductus arteriosus. Am J Physiol Heart Circ Physiol 290: H1660-1670.
21. Yokoyama U, Minamisawa S, Quan H, Ghatak S, Akaike T, et al. (2006) Chronic activation of the prostaglandin receptor EP4 promotes hyaluronan-mediated neointimal formation in the ductus arteriosus. J Clin Invest 116: 3026-3034.
22. Bayston T, Ramessur S, Reise J, Jones KG, Powell JT, (2003) Prostaglandin E2 receptors in abdominal aortic aneurysm and human aortic smooth muscle cells. J Vasc Surg 38: 354-359.
23. Kabashima K, Saji T, Murata T, Nagamachi M, Matsuoka T, et al. (2002) The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Invest 109: 883-893.
24. Wang Y, Ait-Oufella H, Herbin O, Bonnin P, Ramkhelawon B, et al. (2010) TGF-beta activity protects against inflammatory aortic aneurysm progression and complications in angiotensin II-infused mice. J Clin Invest 120: 422-432.
25. Woodward DF, Jones RL, Narumiya S, (2011) International Union of Basic and Clinical Pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress. Pharmacol Rev 63: 471-538.
26. Nataraj C, Thomas DW, Tilley SL, Nguyen MT, Mannon R, et al. (2001) Receptors for prostaglandin E(2) that regulate cellular immune responses in the mouse. J Clin Invest 108: 1229-1235.
27. Steenport M, Khan KM, Du B, Barnhard SE, Dannenberg AJ, et al. (2009) Matrix metalloproteinase (MMP)-1 and MMP-3 induce macrophage MMP-9: evidence for the role of TNF-alpha and cyclooxygenase-2. J Immunol 183: 8119-8127.
28. Pavlovic S, Du B, Sakamoto K, Khan KM, Natarajan C, et al. (2006) Targeting prostaglandin E2 receptors as an alternative strategy to block cyclooxygenase-2-dependent extracellular matrix-induced matrix metalloproteinase-9 expression by macrophages. J Biol Chem 281: 3321-3328.
29. Cipollone F, Fazia ML, Iezzi A, Cuccurullo C, De Cesare D, et al. (2005) Association between prostaglandin E receptor subtype EP4 overexpression and unstable phenotype in atherosclerotic plaques in human. Arterioscler Thromb Vasc Biol 25: 1925-1931.
30. Tang EH, Shvartz E, Shimizu K, Rocha VZ, Zheng C, et al. (2011) Deletion of EP4 on bone marrow-derived cells enhances inflammation and angiotensin II-induced abdominal aortic aneurysm formation. Arterioscler Thromb Vasc Biol 31: 261-269.
31. Takayama K, Garcia-Cardena G, Sukhova GK, Comander J, Gimbrone MA Jr, et al. (2002) Prostaglandin E2 suppresses chemokine production in human macrophages through the EP4 receptor. J Biol Chem 277: 44147-44154.
32. Hishikari K, Suzuki J, Ogawa M, Isobe K, Takahashi T, et al. (2009) Pharmacological activation of the prostaglandin E2 receptor EP4 improves cardiac function after myocardial ischaemia/reperfusion injury. Cardiovasc Res 81: 123-132.
33. Kossakowska AE, Edwards DR, Prusinkiewicz C, Zhang MC, Guo D, et al. (1999) Interleukin-6 regulation of matrix metalloproteinase (MMP-2 and MMP-9) and tissue inhibitor of metalloproteinase (TIMP-1) expression in malignant non-Hodgkin's lymphomas. Blood 94: 2080-2089.